Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VB-111 |
Synonyms | |
Therapy Description |
Ofranergene Obadenovec (VB-111) is an engineered adenovirus that expresses Fas-c specifically within endothelial cells, resulting in endothelial cell death and decreased tumor blood supply, and potentially leading to tumor cell death (PMID: 22701765) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VB-111 | Ofranergene Obadenovec | VB111 | Ofranergene Obadenovec (VB-111) is an engineered adenovirus that expresses Fas-c specifically within endothelial cells, resulting in endothelial cell death and decreased tumor blood supply, and potentially leading to tumor cell death (PMID: 22701765) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02511405 | Phase III | Bevacizumab VB-111 | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) | Completed | USA | ISR | CAN | 0 |